Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology
Transcenta, headquartered in China and with a pipeline of over ten therapeutic antibody candidates, is a clinical-stage biopharmaceutical company with expertise in biologics discovery, translational research, clinical, and process development. The post Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology appeared first on GEN - Genetic Engineering…
Transcenta Therapeutics and WuXi Biologics have formed a partnership aimed at speeding up the commercialization of Transcenta's HiCB technology. Transcenta will grant WuXi Biologics a non-exclusive license to certain HiCB platform technologies and ExcelPro cell culture media. In return, Transcenta will receive an upfront payment of $1.5 million and may receive additional milestone payments for meeting specific conditions.
The collaboration will see WuXi Biologics acting as Transcenta's strategic partner for Central Manufacturing (CMC) development and supporting molecules across the company's development pipeline.
The HiCB platform combines intensified continuous perfusion upstream processing with hybrid continuous downstream purification, resulting in a significant boost in productivity compared to conventional fed-batch processes. Transcenta claims that HiCB can substantially reduce the cost of goods, lower capital investment, and allow for more agile production.
Moreover, HiCB is said to improve recovery yield and product quality, especially for complex biologics. Transcenta, based in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in biologics discovery, translational research, clinical, and process development. The company has a pipeline of over ten therapeutic antibody candidates targeting oncology, bone, and kidney disorders.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
